Phanes Therapeutics’ PT886 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA
- Thursday, June 30, 2022, 7:00
- Finance
- Add a comment
SAN DIEGO, June 30, 2022 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PT886 for the…
About the Author
adminasapcorp has written 41268 stories on this site.